Authors

Omid Hamid, MD, The Angeles Clinic and Research Institute

Latest:

OncLive and the Ruesch Center for the Cure of Gastrointestinal Cancers Announce Recipients of the 2024 Luminary Awards in GI Cancers

OncLive and the Ruesch Center for the Cure of GI Cancers announce the winners of the 2024 Luminary Awards in GI Cancers.

OncLive Breast PX-ESMO-10/5/17 Adam M. Brufsky, MD, PhD, University of Pittsburgh Cancer Institute

OncLive Nursing

Latest:

Noninvasive Stool Test Effectively Detects Colon Cancer

The iFOBT test examines the stool for hidden blood, which could come from anywhere in the GI tract, and possibly indicates a colon tumor or precancerous growths known as polyps.

OncLive Staff

Latest:

Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

OncLive Staff Writer

Latest:

FDA Accepts Sacituzumab Govitecan Application for TNBC

The FDA has accepted a biologics license application for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer who have received at least 2 prior therapies for metastatic disease.

OncLive TV

Latest:

Dr Grunwald on a Real-World Study of Risk Factors For Disease Progression in PV

Michael R. Grunwald, MD, discusses findings from a real-world study of risk factors related to disease progression in polycythemia vera.

OncNurse

Latest:

ASCO Updates Guidelines on Bone-Modifying Drugs in Breast Cancer

ASCO releases new recommendations amid growing therapeutic options and fresh concerns about serious skeletal-related events.

Oncology &amp

Latest:

Age Cutoff for Pap Tests Questioned

More than 12% of newly diagnosed cervical cancers occurred in women aged 70 to 85 years during 2000 to 2006

Oncology & Biotech News

Latest:

Study Shows No Survival Benefit of Cetuximab Over Cisplatin-Based Chemoradiation in Head and Neck Cancers

Patients with locally advanced head and neck cancer gained no survival benefit with the addition of cetuximab to chemoradiation.

Oncology & Biotech News Editors

Latest:

Chemotherapy Foundation Symposium Overview

2008's Chemotherapy Foundation Symposium

Oncology Practice

Ophira Ginsburg, MD

Latest:

Dr. Ginsburg Discusses Cervical Cancer Screening Techniques

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses cervical cancer screening techniques.

Ophira M. Ginsburg, MSc, MD,

Latest:

Dr. Ginsburg on Genetic Testing in Ovarian Cancer Families

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High-Risk Cancer Program, Perlmutter Cancer Center at NYU Langone Medical Center, discusses the importance of genetic testing in ovarian cancer families.

Ophira M. Ginsburg, MSc, MD, FRCPC

Latest:

Dr. Ginsburg on Determining Genetic Testing in Gynecologic Malignancies

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses determining which patients should receive genetic testing for gynecologic malignancies.

Orazio Caffo, MD

Latest:

Dr. Caffo Discusses Enzalutamide/Docetaxel Combination in Frontline mCRPC

Orazio Caffo, MD, director of medical oncology at the Santa Chiara Hospital in Trento, Italy, discusses enzalutamide plus docetaxel combination for the frontline treatment of metastatic castration-resistant prostate cancer.

Othman Al-Sawaf, MD

Latest:

Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines

Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.

Owen A. O'Connor, MD, PhD

Latest:

Dr. O'Connor on Targeting CD30 in DLBCL

Owen A. O'Connor, MD, PhD, professor of Medicine and Experiment Therapies, co-program director, Lymphoid Development and Malignancy Program, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses targeting CD30 expression in patients with diffuse large B-cell lymphoma.

Owen O'Connor

Latest:

Dr. O'Connor on Recent FDA Approvals in MCL

Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the recent FDA approval of acalabrutinib (Calquence) for patients with mantle cell lymphoma (MCL).

Owen O'Connor, MD, PhD

Latest:

Dr. O'Connor on Treatment Options Following Ibrutinib Progression in MCL

Owen O'Connor, MD, PhD, professor of medicine and experimental therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses treatment options following progression on ibrutinib (Imbruvica) for patients with mantle cell lymphoma (MCL).